SCHEMBL4570080

SCHEMBL4570080

CCOC(=O)Nc1ccc(N2CCC[C@]3(CCN(C4CCOCC4)C3=O)C2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.45
SMN1; SMN2 Q16637 5/20 0.45
RAB9A P51151 3/20 0.45
NPC1 O15118 2/20 0.45
TP53 P04637 2/20 0.44
HPGD P15428 2/20 0.44
MAPK1 P28482 2/20 0.44
KMT2A Q03164 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
CYP1A2 P05177 1/20 0.41
POLB P06746 1/20 0.39
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.38
ALOX15 P16050 1/20 0.38
HSD17B10 Q99714 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
KDM4E B2RXH2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17082021 1.00 MAPT (0.45) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL4570089 0.93 SMN1; SMN2 (0.55) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL17082079 0.93 SMN1; SMN2 (0.55) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL4570085 0.91 L3MBTL1 (0.40) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL17082070 0.91 L3MBTL1 (0.40) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL17082022 0.90 SMN1; SMN2 (0.41) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL4570091 0.90 SMN1; SMN2 (0.41) MAPTSMN1; SMN2RAB9ANPC1TP53
SCHEMBL17082012 0.88 CRBN (0.42) MAPTSMN1; SMN2HPGDMAPK1CYP1A2
SCHEMBL4570060 0.88 CRBN (0.42) MAPTSMN1; SMN2HPGDMAPK1CYP1A2
SCHEMBL3705343 0.88 ALDH1A1 (0.41) MAPTSMN1; SMN2RAB9ANPC1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-05-17 US disclosed
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2012-05-17 US disclosed
US-8110581-B2 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-02-07 US disclosed
US-8110581-B2 Lactam compounds and their use as pharmaceuticals INCYTE CORPORATION (US) 2012-02-07 US disclosed
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2009-11-26 US disclosed
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2009-11-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090291946-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 MAPT 3735/4885SMN1; SMN2 3517/4885RAB9A 2128/4885
US-20120122858-A1 LACTAM COMPOUNDS AND THEIR USE AS PHARMACEUTICALS HSD11B1, HSD11B2, HSD17B1 MAPT 3735/4885SMN1; SMN2 3517/4885RAB9A 2128/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.